Could a common vitamin stop liver scarring? new trial aims to find out
NCT ID NCT06599918
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether nicotinamide (a form of vitamin B3) can stop or reverse liver fibrosis in people with non-alcoholic fatty liver disease and obesity. Thirty adults will take either nicotinamide or a placebo daily for one year. Researchers will measure liver stiffness using Fibroscan and check for changes in body fat, weight, and inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nicotinamide (vitamin B3)
- What this could lead to
- If it works, this could point toward a simple vitamin-based treatment to slow or reverse liver scarring in fatty liver disease.
- What could go wrong
- This is a small, early pilot study with only 30 people. It may not show clear benefit, and results may not apply to everyone with liver fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, 08025, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?